Related Experiment Video
Updated: Jul 4, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Genetic polymorphisms and endometrial cancer risk
Larissa A Meyer1, Shannon N Westin, Karen H Lu
1Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman P. Pressler St, CPB 6.3244, Unit 1362, Houston, TX 77030, USA. lmeyer@mdanderson.org
Expert Review of Anticancer Therapy
|July 1, 2008
Summary
Investigating genetic single nucleotide polymorphisms (SNPs) helps understand cancer susceptibility. This review explores SNPs
Area of Science:
- Genetics
- Oncology
- Cancer Epidemiology
Background:
- Most sporadic cancers arise from the cumulative effect of multiple genetic variants, each conferring modest individual risk.
- Understanding genetic susceptibility is crucial for developing personalized cancer prevention strategies.
Purpose of the Study:
- To review recent findings on genetic polymorphisms and their association with endometrial cancer risk.
- To explore the role of candidate single nucleotide polymorphisms (SNPs) in pathways like DNA repair and steroid metabolism.
Main Methods:
- Review of recent genetic association studies.
- Analysis of candidate SNPs in functionally critical genes.
- Exploration of challenges in genetic association studies, including power and bias.
Main Results:
- Genetic polymorphisms in key genes are implicated as risk factors for endometrial cancer.
- Candidate SNPs may influence pathways such as DNA damage repair, cell-cycle control, and apoptosis.
Conclusions:
- Single nucleotide polymorphisms (SNPs) offer potential markers for endometrial cancer risk stratification.
- Further validation of promising findings is essential for effective cancer prevention.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...